Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
6Customers
1Debt Items
18Related Chains
Source-Backed Evidence Depth
Chemomab Therapeutics Ltd. (CMMB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
1Distinct source URLs
1High confidence
0.696Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
Reciprocal relationship from MIRM graph: with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorit…
Reciprocal relationship from EDSA graph: Reciprocal relationship from CMMB graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary…
Reciprocal relationship from MIRM graph: future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced dem…
CHEMOMAB-THERAPEUTICS-INC
CHEMOMAB-THERAPEUTICS-INC
62%
nd for the years ended December 31, 2025, 2024 and 2023, respectively. See Note 12. The accompanying notes are an integral part of the consolidated financial statements. F - 6 Chemomab Therapeutics L…
GENERAL-A-CHEMOMAB-THERAPEUTICS-LTD
GENERAL-A-CHEMOMAB-THERAPEUTICS-LTD
62%
nd for the years ended December 31, 2025, 2024 and 2023, respectively. See Note 12. The accompanying notes are an integral part of the consolidated financial statements. F - 6 Chemomab Therapeutics L…
LIFESCI-CAPITAL-LLC
LIFESCI-CAPITAL-LLC
62%
ogic assessments. Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and biochem…
ROTH-CAPITAL-PARTNERS-LLC
ROTH-CAPITAL-PARTNERS-LLC
62%
ogic assessments. Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and biochem…
Chemomab Therapeutics Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
CMMB-DEBT-8719
Warrants outstanding: 17.35
90%
xbrl warrant detail from xbrl 2021-03-15.
Chemomab Therapeutics Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Chemomab Therapeutics Ltd..
Chemomab Therapeutics Ltd. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Chemomab Therapeutics Ltd..
